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r George T. Christakis (Toronto, Canada). The authors are to be
ongratulated for this work, which adds substantially to the knowl-
dge base of aortic valvular prosthesis size and its purported influence
n operative mortality. The authors have used contemporary data
rom a homogenous population undergoing aortic valve replacement.
he cohort is large with good statistical predictive power. Dr. Bridges
nd his colleagues performed multivariable analyses and demon-
trated that effective orifice area or indexed effective orifice area, but
ot both, were independent predictors of operative mortality follow-
ng aortic valve replacement.
We in Toronto have previously published data confirming an
ncrease in operative mortality following aortic valve replacement
hen the indexed effective orifice area is less than 0.6 cm2/m2. We
emonstrated operative mortalities of 2.1% versus less than 1%
epending on whether they were above or below 0.6 cm2/m2. We
lso demonstrated that an indexed effective orifice area less than
.6 cm2/m2 represented the 10th percentile for patient prosthesis
ize. This is, coincidentally, the exact cutoff Dr Bridges and
olleagues have used to represent the lowest indexed effective
rifice area.
In model 3, where both effective orifice area and indexed
ffective orifice area were used together in the model, the authors
emonstrated that indexed effective orifice area did not predict
perative mortality and only an effective orifice area less than 1.15
m2 barely predicted operative mortality, with a lower-end confi-
ence interval for an OR of 1.04.
Do Dr Bridges and colleagues believe that perhaps effective
rifice area is not a predictor of operative mortality but rather a
linical correlate or a confounding variable or a proxy variable that
ruly predicts operative mortality?
The small valve implant may not have been the cause of death.
his introduces a plethora of questions. Were other variables or
nteractions of other variables tested in the models? What was the
redictive value in the authors’ best model based on a receiving
perating characteristics curve? Could left ventricular function,
ender, or valve lesion be a proxy for effective orifice area? And
am sure many of the sponsoring manufacturers would like to
now whether the type and make of valve influenced the operative
ortality.
Finally, the authors conclude that a small prosthesis size in-
reases operative mortality following AVR, presumably on the
asis of patient-prosthesis mismatch theory, but I believe on the
asis of this conclusion that they do not think that the cause is
emodynamic. An alternative explanation may be that the opera-
ive mortality is increased by the complications associated with
mplanting any valve into a small annulus. Obstruction of coro-
aries, the need to perform aortoplasties or annuloplasties, para-
alvular leaks, and tearing of the aorta from tying in a small hole
re more common in patients with small annuli and friable tissues
hat usually occur in patients like this.
We caution the authors that conclusions that insinuate it is the
mall prosthesis that increases operative mortality rather than the
mall annulus may become a self-fulfilling prophecy. Concerted
ttempts to stuff even larger valves into small annuli may cause
omplications such as torn aortas and obstructed coronaries. Sur-
eons may be compelled to perform aortic root enlargement pro-
edures or other complicated procedures with an accompanying
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Bridges et al Surgery for Acquired Cardiovascular Diseaseigher operative mortality under the false impression that it is the
mall valve that is causing a higher operative mortality.
We suggest that further study is necessary to understand how
mall aortic annuli increase operative mortality, what the mecha-
ism of complications is, and what techniques can be used to
ecrease the complication rate rather than focusing on the size of
he implanted prosthesis. Do the authors know the mechanism of
perative mortality in their patients, and what was the incidence
f aortic root enlargement or aortoplasties?
Dr. Charles R. Bridges (Philadelphia, Pa). Thank you very
uch, Dr. Christakis, for those insightful questions. I will try to
nswer each of them. You asked whether effective orifice area is
othing more than a clinical correlate or a proxy variable for some
ther variable that is actually the cause of increased mortality. We
on’t know the answer to that, but we believe that effective orifice
rea itself is not likely to be the most important variable, and in
act, we actually agree very much with you that small prosthesis
ize may be a surrogate or a proxy for small annular size and the
echnical issues associated with implanting valves in relatively
mall annuli. r
The Journal of ThoracicIn terms of whether there is a relationship of the type and make
f valve, there is a slight difference in mortality for mechanical
rostheses compared to bioprostheses; however, we could not find
ny consistent relationship by manufacturer of mortality, and ob-
iously that was not the primary purpose of this study.
The other point you made was that it probably is the small
nnulus that is the cause of increased mortality associated with
mall prostheses, not the size of the prosthesis itself. Our
nalysis suggests that hemodynamics is not an important factor
n the increased mortality associated with these small valves. If
t were, we would have expected that the mortality would have
otten even higher when small valves were placed in larger
atients. In fact, we did not find that to be the case, which
nderlines and echoes your point that it may have little to do
ith hemodynamics.
And I wholeheartedly agree with your assertion that an attempt
o put larger valves in small patients, simply based on arbitrary
utoffs, may actually do more harm than good, although that
ould need to be the subject of an additional study, ideally, aandomized trial.
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